03789nam 2200565 450 991046479410332120200520144314.088-97419-48-8(CKB)3710000000118108(EBL)3034685(SSID)ssj0001399529(PQKBManifestationID)11867888(PQKBTitleCode)TC0001399529(PQKBWorkID)11450653(PQKB)11170189(MiAaPQ)EBC3034685(Au-PeEL)EBL3034685(CaPaEBR)ebr10960571(OCoLC)880938340(EXLCZ)99371000000011810820141106d2013 uy| 0engur|n|---|||||txtccrMultiple sclerosis a guide to pharmacologic treatment /D. OntanedaFirst edition.Torino, Italy :SEEd,2013.1 online resource (150 p.)Description based upon print version of record.88-97419-47-X Includes bibliographical references.""Title Page""; ""Colophon""; ""Table of Contents""; ""Section I. Introduction""; ""Scope""; ""New Therapies and Risks""; ""Overview of Multiple Sclerosis""; ""Basic pathogenesis""; ""Disease forms""; ""Approach to treatment""; ""Goals of treatment""; ""Challenges""; ""References""; ""Section II. Disease Modifying Agents for Multiple Sclerosis""; ""Interferon for MS""; ""Introduction""; ""Mechanism of Action""; ""Efficacy""; ""Safety and Risks""; ""Conclusions""; ""References""; ""Glatiramer acetate for MS""; ""Introduction""; ""Mechanism of Action""; ""Efficacy""; ""Safety and Risks""""Conclusions""""References""; ""Mitoxantrone for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Natalizumab for MS""; ""Introduction""; ""Mechanism of Action""; ""Efficacy""; ""Safety and Risks""; ""Conclusions""; ""References""; ""Fingolimod for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Teriflunomide for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusion""; ""References""""Dimethyl fumarate for MS""""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Section III. Treatment of relapses""; ""Defining Relapses""; ""Introduction""; ""Relapse symptoms""; ""MRI in MS Relapses""; ""Natural History of MS Relapses""; ""References""; ""Treatment of MS relapses""; ""Introduction""; ""Corticosteroids (CS) and ACTH""; ""Plasma exchange""; ""IVIG""; ""References""; ""Section IV. Emerging therapies for multiple sclerosis""; ""Laquinimod for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""""Safety and risks""""Conclusions""; ""References""; ""Alemtuzumab for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Daclizumab for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Ocrelizumab and Rituximab for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Author""Multiple sclerosisTreatmentPharmacologyElectronic books.Multiple sclerosisTreatment.Pharmacology.Ontaneda D.920527MiAaPQMiAaPQMiAaPQBOOK9910464794103321Multiple sclerosis2064566UNINA00716cam0 2200241 450 E60020003808020221213081355.020080624d1990 |||||ita|0103 bagerDE<<Die >>SchereErnst JüngerStuttgartKlett-Cotta1990186 p.22 cm.Jünger, ErnstAF00014102070384811ITUNISOB20221213RICAUNISOBUNISOB83081777E600200038080M 102 Monografia moderna SBNM830000262Si81777acquistobethUNISOBUNISOB20080624115958.020201130131104.0bethbSchere1685955UNISOB